Vox Markets Logo
2nd September 2024
06:00

AIM - Cancellation - ReNeuron Group Plc

30th August 2024
06:00

ReNeuron Group plc - Corporate update and AIM cancellation

2nd August 2024
11:25

ReNeuron Group plc - Corporate Update

26th June 2024
14:33

ReNeuron Group plc - Change of Registered Address

5th June 2024
14:36

ReNeuron Group plc - Creditor’s decision on Administrators' Proposals

17th May 2024
11:45

ReNeuron Group plc - Publication of Joint Administrators' Proposals

8th May 2024
06:00

ReNeuron Group plc - Update on Administration Process

17th April 2024
10:30

ReNeuron Group plc - Directorate Change

20th March 2024
12:30

ReNeuron Group plc - Intention to Appoint Administrators

1st March 2024
07:00

ReNeuron Group plc - Block Listing Review & Total Voting Rights

5th February 2024
14:30

AIM - Suspension - ReNeuron Group plc

5th February 2024
14:30

ReNeuron Group plc - Corporate update and suspension of trading on AIM

8th November 2023
07:01

ReNeuron Group plc - Interim Results for the six months ended 30 Sept

8th November 2023
07:00

ReNeuron Group plc - ReNeuron presents in vivo data at Cell 2023

4th September 2023
06:00

ReNeuron Group plc - R&D Update

1st September 2023
06:00

ReNeuron Group plc - Block Listing Review & Total Voting Rights

29th August 2023
06:00

ReNeuron Group plc - Director declaration

22nd August 2023
09:34

ReNeuron Group plc - Result of AGM

24th July 2023
16:20

ReNeuron Group plc - Notice of AGM

12th July 2023
10:57

ReNeuron Group plc - Share Purchase by Chief Financial Officer

ReNeuron Group Plc (RENE.L) Share Price & News


Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -M
  • LOW
    -
  • CLOSE
    -
  • SHARES IN ISSUE
    57.17M

ReNeuron Group Plc Company Profile

We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

Watchlist